Sorbonne Paris Cité, Faculté de Médecine, Assistance Publique-Hôpitaux de Paris (AP- HP), Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire (CHU) Cochin, Service d'Histologie-Embryologie-Biologie de la Reproduction, Université Paris Descartes, Paris, France.
Département "Génomique, Epigénétique et Physiopathologie de la Reproduction," Institut Cochin, INSERM U1016, CNRS UMR8104, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
J Assist Reprod Genet. 2018 Oct;35(10):1843-1850. doi: 10.1007/s10815-018-1251-0. Epub 2018 Jul 4.
This study was designed to evaluate patient management and quality of information given by French oncologists to cancer women concerning fertility issues and possibilities of fertility preservation.
An online survey was sent to 1161 physicians in all major cancer centers throughout France between May 2012 and January 2013.
A total of 102 responses were received and analyzed. Only 46% of all physicians surveyed reported discussing infertility risks with patients of reproductive age and 22% referred them to a fertility center before beginning treatments. Only 14% of practitioners considered themselves knowledgeable in FP techniques and ovarian transposition was the most frequently mentioned technique in consultation.
This study is at the best of our knowledge the first nationwide survey to assess the state of the art in oncofertility management. It highlights inadequate management of fertility preservation for female patients in France. Physicians reported lacking knowledge and tools that would allow them to provide patients with appropriate information. A better collaboration between cancer and fertility centers needs to be organized in France as already organized in other countries.
本研究旨在评估法国肿瘤学家向癌症女性提供有关生育问题和生育保存可能性的患者管理和信息质量。
2012 年 5 月至 2013 年 1 月期间，我们向法国所有主要癌症中心的 1161 名医生在线发送了一份调查问卷。
共收到并分析了 102 份回复。只有 46%的被调查医生报告与育龄患者讨论过不孕风险，22%的医生在开始治疗前将患者转介到生育中心。只有 14%的医生认为自己对 FP 技术有足够的了解，在咨询中最常提到的技术是卵巢移位。
据我们所知，这是第一项评估法国生育肿瘤学管理现状的全国性调查。它强调了法国对女性患者生育保存管理的不足。医生报告称缺乏知识和工具，无法为患者提供适当的信息。法国需要像其他国家一样，在癌症和生育中心之间组织更好的合作。
